Aberdeen Group plc Sells 15,449 Shares of Ascendis Pharma A/S $ASND

Key Points

• Aberdeen Group plc has reduced its stake in Ascendis Pharma A/S by 8.3%, now owning 171,731 shares worth $26.77 million.
• Ascendis Pharma A/S reported a loss of ($0.93) EPS, beating analysts' estimates, and generated $216.28 million in revenue for the last quarter.
• Investment analysts have rated Ascendis Pharma A/S with a consensus target price of $243.36, with 15 analysts rating it as a "Buy."

Aberdeen Group plc lessened its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 8.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 171,731 shares of the biotechnology company's stock after selling 15,449 shares during the quarter. Aberdeen Group plc owned 0.28% of Ascendis Pharma A/S worth $26,766,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in ASND. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Ascendis Pharma A/S in the 4th quarter worth about $28,000. Quarry LP bought a new stake in shares of Ascendis Pharma A/S in the 4th quarter worth about $96,000. Tower Research Capital LLC TRC lifted its holdings in shares of Ascendis Pharma A/S by 195.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,004 shares of the biotechnology company's stock worth $138,000 after acquiring an additional 664 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Ascendis Pharma A/S in the 4th quarter worth about $174,000. Finally, Dearborn Partners LLC bought a new stake in shares of Ascendis Pharma A/S in the 1st quarter worth about $203,000.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on ASND shares. Wall Street Zen upgraded shares of Ascendis Pharma A/S from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Morgan Stanley started coverage on shares of Ascendis Pharma A/S in a report on Thursday, July 3rd. They issued an "overweight" rating and a $250.00 target price for the company. Wedbush raised their target price on shares of Ascendis Pharma A/S from $212.00 to $220.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. Citigroup reaffirmed a "buy" rating and issued a $290.00 price target (up previously from $243.00) on shares of Ascendis Pharma A/S in a research note on Friday, August 8th. Finally, Royal Bank Of Canada raised their price target on shares of Ascendis Pharma A/S from $210.00 to $230.00 and gave the stock an "outperform" rating in a research note on Friday, August 8th. Fifteen equities research analysts have rated the stock with a Buy rating, According to MarketBeat, Ascendis Pharma A/S has an average rating of "Buy" and an average price target of $243.36.

Ascendis Pharma A/S Stock Up 0.8%

ASND stock traded up $1.50 during trading on Friday, hitting $194.30. The company had a trading volume of 308,107 shares, compared to its average volume of 572,249. The firm has a market capitalization of $11.89 billion, a P/E ratio of -37.66 and a beta of 0.41. Ascendis Pharma A/S has a 52-week low of $111.09 and a 52-week high of $199.99. The company has a 50 day simple moving average of $178.20 and a 200-day simple moving average of $163.71.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) EPS for the quarter, beating analysts' consensus estimates of ($1.42) by $0.49. The business had revenue of $216.28 million for the quarter, compared to analysts' expectations of $163.17 million. Sell-side analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.